Khor Jia Ker1, Noelle M Teske2, Rui Feng3, Benjamin F Chong4, Victoria P Werth5. 1. National Skin Centre, Singapore, Singapore; Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania. 2. Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas. 3. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: ben.chong@utsouthwestern.edu. 5. Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania; Medical Research, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania. Electronic address: werth@mail.med.upenn.edu.
Abstract
BACKGROUND: Long-term studies characterizing disease course of cutaneous lupus erythematosus (CLE) patients on standard-of-care treatments are lacking. OBJECTIVE: We characterized and compared disease course of CLE patients using Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). METHODS: In total, 83 CLE patients with CLASI scores collected from ≥3 study visits within 2 years had disease activity and damage trends calculated by average change scores (ACS). Trends were classified as improved (ACS ≤-3), worsened (ACS ≥3), or stable (-3 < ACS < 3). Linear regression models compared CLASI trends between groups. RESULTS: Most patients (72.73%) with initial CLASI activity (CLASI-A) scores >9 (N = 33) had improved disease activity versus 14.00% of those with initial CLASI-A scores ≤9 (N = 50). Linear regression analyses showed significant improvement in CLASI-A scores in patients of minority races (P < .05), with baseline CLASI-A scores >9 (P < .0001), baseline CLASI damage (CLASI-D) scores ≥10 (P = .0001), and CLE disease duration ≤1 year (P = .01). Of 28 patients with baseline CLASI-D scores ≥10, 35.71% had improvements in damage, while 5.26% of patients with initial CLASI-D scores of 5-9 (N = 19) and 0% with initial CLASI-D scores <5 (N = 36) (P = .0005) had improvements. LIMITATIONS: Limitations include small sample size. CONCLUSION: Baseline CLASI-A score >9, minority race, and short disease duration predict CLE disease activity improvement. A baseline CLASI-D score ≥10 is associated with disease damage improvement.
BACKGROUND: Long-term studies characterizing disease course of cutaneous lupus erythematosus (CLE) patients on standard-of-care treatments are lacking. OBJECTIVE: We characterized and compared disease course of CLEpatients using Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). METHODS: In total, 83 CLEpatients with CLASI scores collected from ≥3 study visits within 2 years had disease activity and damage trends calculated by average change scores (ACS). Trends were classified as improved (ACS ≤-3), worsened (ACS ≥3), or stable (-3 < ACS < 3). Linear regression models compared CLASI trends between groups. RESULTS: Most patients (72.73%) with initial CLASI activity (CLASI-A) scores >9 (N = 33) had improved disease activity versus 14.00% of those with initial CLASI-A scores ≤9 (N = 50). Linear regression analyses showed significant improvement in CLASI-A scores in patients of minority races (P < .05), with baseline CLASI-A scores >9 (P < .0001), baseline CLASI damage (CLASI-D) scores ≥10 (P = .0001), and CLE disease duration ≤1 year (P = .01). Of 28 patients with baseline CLASI-D scores ≥10, 35.71% had improvements in damage, while 5.26% of patients with initial CLASI-D scores of 5-9 (N = 19) and 0% with initial CLASI-D scores <5 (N = 36) (P = .0005) had improvements. LIMITATIONS: Limitations include small sample size. CONCLUSION: Baseline CLASI-A score >9, minority race, and short disease duration predict CLE disease activity improvement. A baseline CLASI-D score ≥10 is associated with disease damage improvement.
Authors: Joerg Albrecht; Lynne Taylor; Jesse A Berlin; Samuel Dulay; Gina Ang; Steven Fakharzadeh; Jonathan Kantor; Ellen Kim; Giuseppe Militello; Karen McGinnis; Stephen Richardson; James Treat; Carmela Vittorio; Abby Van Voorhees; Victoria P Werth Journal: J Invest Dermatol Date: 2005-11 Impact factor: 8.551
Authors: A Kuhn; J Sigges; C Biazar; V Ruland; N Patsinakidis; A Landmann; S Amler; G Bonsmann Journal: Br J Dermatol Date: 2014-08-25 Impact factor: 9.302
Authors: Yesenia Santiago-Casas; Luis M Vilá; Gerald McGwin; Ryan S Cantor; Michelle Petri; Rosalind Ramsey-Goldman; John D Reveille; Robert P Kimberly; Graciela S Alarcón; Elizabeth E Brown Journal: Arthritis Care Res (Hoboken) Date: 2012-05 Impact factor: 4.794
Authors: G S Alarcón; A W Friedman; K V Straaton; J M Moulds; J Lisse; H M Bastian; G McGwin; A A Bartolucci; J M Roseman; J D Reveille Journal: Lupus Date: 1999 Impact factor: 2.911
Authors: E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester Journal: Arthritis Rheum Date: 1982-11
Authors: Zuleika L Bonilla-Martinez; Joerg Albrecht; Andrea B Troxel; Lynne Taylor; Joyce Okawa; Sam Dulay; Victoria P Werth Journal: Arch Dermatol Date: 2008-02